Panacea Biotec

Ambala, India Founded: 1984 • Age: 42 yrs Listed
Developer of biosimilars, vaccines and natural products
Request Access
Report Incorrect Data
Page last updated

About Panacea Biotec

Panacea Biotec is a publicly listed company based in Ambala (India) founded in 1984. Developer of biosimilars, vaccines and natural products. The company has 1,290 employees. Its website panaceabiotec.com draws about 16 thousand monthly visits. Its Indian entity Panacea Biotec Limited reported revenue of ₹676 Cr. Its focus areas include Diversified Pharmaceuticals, Biopharma Outsourcing, CDMO and Diversified. Its competitors include Syngene and Piramal Group; 1 of its 2 listed competitors has raised funding.

Company details

Panacea Biotec involved in research, manufacturing and marketing of branded pharmaceutical formulations, vaccines, biosimilars (antibodies, proteins) and natural products. The product portfolio includes prescription products in therapeutic areas like pain management, diabetes, cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastrointestinal care products and vaccines.

  • Headquarters Ambala, India
  • Employees 1,290
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website panaceabiotec.com
  • Social LinkedIn X Facebook
  • Legal Name Panacea Biotec Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹2,209 Cr

    PANACEABIO · NSE

  • Share Price
    ₹353.70

    -1.93% today

  • Revenue
    ₹640 Cr

    FY 2025-26 · +14.4% YoY

  • EBITDA
    −₹4.66 Cr

    Margin -0.7%

  • Net Profit
    −₹24.44 Cr

    FY 2025-26 · +42.7% YoY

  • Latest Funding Round
    $144M (USD), Post-IPO

    Apr 2019

  • Investors
    India Resurgence Fund
  • Employee Count
    1,290

Funding Insights of Panacea Biotec

  • Total Rounds 2
  • Last Round Post-IPO — $144M
  • First Round $4.6M

    (Sep 2011)

  • Investors Count 1

All 2 funding rounds of Panacea Biotec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2019$144MPost-IPO––
India Resurgence Fund
Sep 2011$4.6MDebt – Conventional––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Panacea Biotec

Panacea Biotec has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include India Resurgence Fund.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
India Resurgence Fund
Distressed and special situations investments across various sectors in India.
2016indiarf.comMumbai, India
Premium access

Investor details for Panacea Biotec

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Panacea Biotec Limited (Panacea Biotec)

Panacea Biotec Limited is the primary company behind Panacea Biotec. The boards of the 2 registered companies of Panacea Biotec currently have 12 directors; the longest-serving is Sandeep Jain, appointed in 1984. 34 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sandeep Jain
DIN 00012973
Managing Director15 Nov 198441 yrs 11 moPanacea Biotec Limited
Ankesh Jain
DIN 03556647
Whole-time director22 Mar 20197 yrs 7 moPanacea Biotec Pharma Limited, Panacea Biotec Limited
Rajesh Jain
DIN 00013053
Managing Director22 Mar 20197 yrs 7 moPanacea Biotec Pharma Limited, Panacea Biotec Limited
Manjula Upadhyay
DIN 07137968
Director23 Jul 20215 yrs 3 moPanacea Biotec Pharma Limited
Narotam Kumar Juneja
DIN 01204817
Whole-time director01 Apr 20224 yrs 7 moPanacea Biotec Pharma Limited
Ambika Sharma
DIN 08201798
Director14 Feb 20242 yrs 8 moPanacea Biotec Limited
Rajesh Jain
DIN 10619014
Director12 Nov 20241 yr 11 moPanacea Biotec Pharma Limited, Panacea Biotec Limited
Sanjay Trehan
DIN 10936402
Whole-time director13 Feb 20251 yr 8 moPanacea Biotec Pharma Limited, Panacea Biotec Limited
Krishan Kumar Jalan
DIN 01767702
Director14 Feb 20251 yr 8 moPanacea Biotec Limited
Harshet Jain
DIN 08732974
Whole-time director14 Feb 20251 yr 8 moPanacea Biotec Limited
Venkatesh Sarvasiddhi
DIN 09326552
Director14 Feb 20251 yr 8 moPanacea Biotec Limited
Rajender Pal Singh
DIN 10198810
Director14 Feb 20251 yr 8 moPanacea Biotec Limited

People of Panacea Biotec

2 people are tracked at Panacea Biotec (2 in leadership); the tracked headcount is 1,290.

NameRoleGroup
Rajesh Jain
Managing DirectorLeadership
Devender Gupta
Chief Financial OfficerLeadership
Premium access

Complete people profiles for Panacea Biotec

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Panacea Biotec

Panacea Biotec is a publicly listed company on the NSE with ticker symbol PANACEABIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Sep 2000
  • Listed onBSE: 531349
  • Listed entityPanacea Biotec Limited
  • Exchange sectorHealth technology
  • ISININE922B01023
  • Share price₹359.20 (+2.76% on the day) · 2026-10-14
  • Market capitalisation₹2,138 Cr
  • EPS (diluted, trailing year)₹-1.16
  • Volume (last session)58,515

Financials of Panacea Biotec

Exchange-reported figures of Panacea Biotec Limited, the listed company behind Panacea Biotec (NSE: PANACEABIO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹640 Cr
+14.4% YoY
EBITDA
−₹4.66 Cr
+82.0% YoY
Profit After Tax
−₹24.44 Cr
+42.7% YoY
Net Worth
₹844 Cr
+0.2% YoY
Total Assets
₹890 Cr
-1.0% YoY
Total Debt
₹15.00 Cr
0.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue640559559460661625544
Revenue growth+14.4%-0.0%+21.6%-30.4%+5.8%+14.8%-
EBITDA(4.66)(25.92)(20.07)(97.96)(13.19)75.189.53
EBITDA margin-0.7%-4.6%-3.6%-21.3%-2.0%+12.0%+1.8%
Profit before tax(7.37)(7.96)1.4712.801,449(146)(178)
Net profit(24.44)(42.65)(33.97)(94.64)(197)(148)(160)
Net profit margin-3.8%-7.6%-6.1%-20.6%-29.8%-23.6%-29.4%
EPS (₹)(0.88)(1.37)(0.19)(5.43)176.05(24.11)(31.72)
Balance sheet
Total assets8908999099219838131,064
Net worth844842848849877(229)199
Total debt15.0015.0015.0015.2434.16820742
Cash & bank64.3710713922658313689.75
Net working capital154206136219169146357
Cash flow
Cash from operations16.69(27.37)(0.10)(422)(108)107(30.47)
Cash from investing(40.46)64.9810.234301,283(47.79)(34.52)
Cash from financing(1.06)(2.66)(2.81)(18.37)(1,176)(47.11)90.74
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue200167165141167133163147
Revenue growth (YoY)+19.7%+25.8%+1.0%-4.2%+44.1%---
Other income6.985.265.059.1016.9936.306.397.42
EBITDA5.672.5711.74(17.79)(1.18)(26.88)7.967.00
EBITDA margin+2.8%+1.5%+7.1%-12.6%-0.7%-20.3%+4.9%+4.8%
Depreciation7.907.888.458.348.398.428.988.68
Interest1.181.201.852.140.861.040.990.98
Profit before tax3.57(1.25)6.49(19.17)6.56(0.04)4.384.76
Tax1.37(0.25)2.60(5.16)2.601.95(0.06)0.05
Net profit2.20(1.00)3.89(14.01)3.96(1.99)4.444.71
EPS (₹)0.380.080.65(2.20)0.66(0.31)0.740.77
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue413310360257236344158
Revenue growth+33.4%-13.8%+39.9%+9.2%-31.5%+117.3%-
EBITDA(17.84)(6.92)14.15(62.62)(72.69)0.46(135)
EBITDA margin-4.3%-2.2%+3.9%-24.4%-30.9%+0.1%-85.2%
Profit before tax(43.90)(26.05)4.19(62.74)(93.59)(12.88)(136)
Net profit(29.93)(15.28)3.48(92.83)(93.60)(17.70)(122)
Net profit margin-7.2%-4.9%+1.0%-36.1%-39.8%-5.2%-77.0%
EPS (₹)(4.88)(2.49)0.58(14.29)(15.28)(2.36)(24.99)
Balance sheet
Total assets584572480448515594978
Net worth294321335331415508893
Total debt25622111997.4784.1665.0867.24
Cash & bank8.1262.1711.9643.2542.6988.9660.61
Net working capital18.4641.57(65.64)(51.66)2.1396.03454
Cash flow
Cash from operations(40.17)3.9433.07(10.74)(52.69)38.27(82.86)
Cash from investing(18.46)(60.60)(46.80)2.4139.54(37.32)(16.58)
Cash from financing22.5490.0712.829.019.83(7.20)109
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13511199.3190.8111267.9010876.64
Revenue growth (YoY)+20.0%+63.7%-8.4%+18.5%+97.4%---
Other income6.065.603.843.614.956.093.323.41
Total expenses12711110110511586.4793.0469.90
EBITDA7.300.30(1.38)(13.70)(3.02)(18.57)15.396.74
EBITDA margin+5.4%+0.3%-1.4%-15.1%-2.7%-27.3%+14.2%+8.8%
Depreciation4.474.184.894.914.774.915.215.09
Interest6.896.337.045.936.004.643.853.76
Profit before tax2.00(4.61)(9.47)(20.93)(8.84)(22.03)9.651.30
Tax0.61(4.43)(2.11)(5.29)(2.14)(9.64)0.000.01

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue200167165141167133163147
Revenue growth (YoY)+19.7%+25.8%+1.0%-4.2%+44.1%---
Other income6.985.265.059.1016.9936.306.397.42
EBITDA5.672.5711.74(17.79)(1.18)(26.88)7.967.00
EBITDA margin+2.8%+1.5%+7.1%-12.6%-0.7%-20.3%+4.9%+4.8%
Depreciation7.907.888.458.348.398.428.988.68
Interest1.181.201.852.140.861.040.990.98
Profit before tax3.57(1.25)6.49(19.17)6.56(0.04)4.384.76
Tax1.37(0.25)2.60(5.16)2.601.95(0.06)0.05
Net profit2.20(1.00)3.89(14.01)3.96(1.99)4.444.71
EPS (₹)0.380.080.65(2.20)0.66(0.31)0.740.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue640559559460661625544
Revenue growth+14.4%-0.0%+21.6%-30.4%+5.8%+14.8%-
Other income36.4056.6561.831541,68710.0530.02
Total expenses644585579558674550535
Employee cost0.00173150126183156142
EBITDA(4.66)(25.92)(20.07)(97.96)(13.19)75.189.53
EBITDA margin-0.7%-4.6%-3.6%-21.3%-2.0%+12.0%+1.8%
Depreciation33.0634.8136.7139.1243.7845.5943.22
Interest6.053.883.584.44181185174
Profit before tax(7.37)(7.96)1.4712.801,449(146)(178)
Tax(0.21)0.772.9846.553711.9516.64
Net profit(24.44)(42.65)(33.97)(94.64)(197)(148)(160)
Net profit margin-3.8%-7.6%-6.1%-20.6%-29.8%-23.6%-29.4%
EPS (₹)(0.88)(1.37)(0.19)(5.43)176.05(24.11)(31.72)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.7913.3312.1211.116.136.136.13
Reserves & surplus807807814816849(256)139
Shareholders' funds (net worth)844842848849877(229)199
Minority interest(5.96)(4.17)(3.82)(3.49)(2.98)(3.00)(3.04)
Secured loans0.000.000.000.240.29760709
Unsecured loans15.0015.0015.0015.0033.8760.0333.55
Total debt15.0015.0015.0015.2434.16820742
Total liabilities8908999099219838131,064
Assets
Gross block1,3871,3461,3271,3311,3171,2621,275
Net block576567582600622609657
Capital work in progress14412810242.3217.2634.4224.01
Investments10.103.2240.4313.495.070.075.58
Inventories193214178202213174148
Sundry debtors73.5272.5657.4260.0981.6684.6868.52
Cash & bank balances64.3710713922658313689.75
Loans & advances17218069.9860.7367.90116377
Total current assets503573445549946511683
Total current liabilities349367309330776365326
Net working capital154206136219169146357
Total assets8908999099219838131,064
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash82.1347.1739.8550.3552.0840.2214.47
Net cash from operating activities16.69(27.37)(0.10)(422)(108)107(30.47)
Net cash from investing activities(40.46)64.9810.234301,283(47.79)(34.52)
Net cash from financing activities(1.06)(2.66)(2.81)(18.37)(1,176)(47.11)90.74
Net change in cash(24.82)34.957.32(10.50)(1.74)11.8625.75
Closing cash64.3710713922658313689.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.4%-0.0%+21.6%-30.4%+5.8%+14.8%-
EBITDA growth+82.0%-29.2%+79.5%-642.7%-117.5%+688.9%-
PBT growth+7.4%--88.5%-99.1%+9998.0%+18.0%-
Net income growth+42.7%-25.6%+64.1%+52.0%-33.4%+7.6%-
Revenue CAGR (3Y)+11.6%-5.4%-3.6%-5.4%+13.1%+1.8%0.0%
EBITDA CAGR (3Y)-63.8%+25.3%---53.9%-3.5%-41.3%
Profitability & leverage
Net income margin-1.1%-1.6%-0.3%-7.3%+163.1%-23.6%-35.7%
Return on capital employed--4.3%-3.3%-9.5%-5.1%0.0%0.0%
Return on net worth--5.1%-4.1%-11.1%-60.8%0.0%0.0%
Debt / equity-0.020.020.031.320.002.53
Long-term debt / equity-0.020.020.031.230.002.19
Interest cover-16.04-6.39-6.31-3.24-317.43626.36-516.41
Efficiency & per share
Fixed asset turnover-0.420.420.350.510.490.41
Inventory turnover-2.862.942.223.423.884.75
Debtors turnover-8.609.526.497.958.166.92
EPS (₹)(0.88)(1.37)(0.19)(5.43)176.05(24.11)(31.72)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00132.76133.94134.20139.59(40.87)23.67
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13511199.3190.8111267.9010876.64
Revenue growth (YoY)+20.0%+63.7%-8.4%+18.5%+97.4%---
Other income6.065.603.843.614.956.093.323.41
Total expenses12711110110511586.4793.0469.90
EBITDA7.300.30(1.38)(13.70)(3.02)(18.57)15.396.74
EBITDA margin+5.4%+0.3%-1.4%-15.1%-2.7%-27.3%+14.2%+8.8%
Depreciation4.474.184.894.914.774.915.215.09
Interest6.896.337.045.936.004.643.853.76
Profit before tax2.00(4.61)(9.47)(20.93)(8.84)(22.03)9.651.30
Tax0.61(4.43)(2.11)(5.29)(2.14)(9.64)0.000.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue413310360257236344158
Revenue growth+33.4%-13.8%+39.9%+9.2%-31.5%+117.3%-
Other income18.0016.6224.9134.4412.5720.7530.88
Total expenses431317345320308343293
Employee cost10097.0286.5371.0372.5059.4746.64
EBITDA(17.84)(6.92)14.15(62.62)(72.69)0.46(135)
EBITDA margin-4.3%-2.2%+3.9%-24.4%-30.9%+0.1%-85.2%
Depreciation18.7520.2921.0924.5026.4326.5726.91
Interest25.3115.4613.7810.067.047.525.27
Profit before tax(43.90)(26.05)4.19(62.74)(93.59)(12.88)(136)
Tax(13.97)(10.83)0.6624.790.001.5617.10
Net profit(29.93)(15.28)3.48(92.83)(93.60)(17.70)(122)
Net profit margin-7.2%-4.9%+1.0%-36.1%-39.8%-5.2%-77.0%
EPS (₹)(4.88)(2.49)0.58(14.29)(15.28)(2.36)(24.99)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.7913.3312.1211.116.136.136.13
Reserves & surplus257286301298387480833
Shareholders' funds (net worth)294321335331415508893
Secured loans0.000.000.000.240.295.0512.44
Unsecured loans25622111997.2383.8760.0354.80
Total debt25622111997.4784.1665.0867.24
Total liabilities584572480448515594978
Assets
Gross block883863901909908893905
Net block417416423435454464499
Capital work in progress13111996.5427.850.8812.973.74
Investments0.270.270.270.270.270.272.55
Inventories12615210811612987.0499.23
Sundry debtors30.6820.8511.0812.2723.3235.2917.69
Cash & bank balances8.1262.1711.9643.2542.6988.9660.61
Loans & advances11989.9252.5327.5253.5781.26437
Total current assets284325184199249293614
Total current liabilities266283249251247197161
Net working capital18.4641.57(65.64)(51.66)2.1396.03454
Total assets584572480448515594978
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash38.505.096.015.338.6614.924.96
Net cash from operating activities(40.17)3.9433.07(10.74)(52.69)38.27(82.86)
Net cash from investing activities(18.46)(60.60)(46.80)2.4139.54(37.32)(16.58)
Net cash from financing activities22.5490.0712.829.019.83(7.20)109
Net change in cash(36.09)33.41(0.91)0.67(3.32)(6.26)9.96
Closing cash8.1262.1711.9643.2542.6988.9660.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+33.4%-13.8%+39.9%+9.2%-31.5%+117.3%-
EBITDA growth-157.8%-148.9%+122.6%+13.9%-+100.3%-
PBT growth-68.5%-+9998.0%+33.0%-626.6%+90.5%-
Net income growth-95.9%-539.1%+103.8%+0.8%-428.8%+85.5%-
Revenue CAGR (3Y)+17.2%+9.6%+1.5%+17.6%+34.8%+23.2%-33.2%
EBITDA CAGR (3Y)-34.2%-54.3%+213.3%-22.5%-20.9%--
Profitability & leverage
Net income margin-7.2%-4.9%+1.0%-34.1%-39.7%-4.2%-96.8%
Return on capital employed0.0%0.0%+3.3%0.0%0.0%-1.1%-8.2%
Return on net worth0.0%0.0%+0.9%0.0%0.0%-2.5%-18.6%
Debt / equity0.780.520.320.240.160.090.58
Long-term debt / equity0.640.410.320.240.160.090.42
Interest cover-69.17-56.82-198.56-11.55-7.10-28.80-3.26
Efficiency & per share
Fixed asset turnover0.470.350.400.280.260.380.18
Inventory turnover2.972.383.212.102.183.692.23
Debtors turnover16.0519.4130.8014.458.0412.977.37
EPS (₹)(4.88)(2.49)0.58(14.29)(15.28)(2.36)(24.99)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)43.0347.7250.2049.6364.2479.43136.97

Timeline of Panacea Biotec

4 dated milestones of Panacea Biotec across 35 years, from founding to its latest funding, stage changes and deals.

  1. Founded Panacea Biotec is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $4.6M.
  4. Funding Latest funding round, Post-IPO, of $144.0M.

Competitors of Panacea Biotec

Panacea Biotec has 2 listed competitors in our database, 1 of them funded. They include Syngene and Piramal Group.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Syngene
syngeneintl.com1993Bengaluru, India$85.89M5,618
Provider of contract research and manufacturing services for both small molecules and biologics
Piramal Group
piramal.com1984Mumbai, India204
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
Premium access

Detailed competitors of Panacea Biotec

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Panacea Biotec

The website of Panacea Biotec (panaceabiotec.com) receives about 16.2K visits a month.

  • Monthly visits
    16.2K

    ▲ 50.6% vs previous month

Similar websites

Websites whose visitors overlap most with Panacea Biotec. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
panacea-biotec.com
panacea-biotec.com
100%
–
Pharma Vends
pharmavends.com
91%
#1,043,069View details
Cipla
cipla.com
89%
200.9K#203,362View details
avalonpharma.com
avalonpharma.com
88%
#11,834,034–
Lek
lek.si
88%
30.5K#1,031,709View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 28 similar websites and full traffic analytics for Panacea Biotec

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 28 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Panacea Biotec (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Panacea Biotec

Panacea Biotec Faces Rs 9.82 Crore Income Tax Penalty Demand for Alleged Income Misreporting
Medical Dialogues • 1 month ago
Panacea Biotec Receives Letter Of Award For BOPV Supply Worth $8.205 Million
Reuters • 3 months ago
Panacea Biotec Unit Gets Show Cause Notice Alleging Total Tax Liability Of 40.6 Million Rupees
Reuters • 3 months ago
Panacea Biotec Files Appeal Against Fourth Industrial Tribunal (Mohali) Award
Reuters • 3 months ago
Buzzing Stocks: RVNL, Panacea Biotec tally up to 8%; NLC India slides after govt announces OFS
Moneycontrol • 5 months ago
Panacea Biotec Launches Denstar Project To Advance Dengiall Licensure In Sub-Saharan Africa
Reuters • 5 months ago
Panacea Biotec Ltd Receives Rectified Order With Tax Demand Reduced From 457.1 Mln Rupees To Nil
Reuters • 7 months ago
Panacea Biotec Gets Tax Demand Order For 228.8 Million Rupees
Reuters • 7 months ago
Panacea Biotec Says Appeals Body Dismisses Its Appeal Against 93.8 Million Rupees Tax Demand
Reuters • 7 months ago
Panacea Biotec Says Tribunal Order Deletes All Expense Disallowances, Cancels 3.29 Billion Rupees Tax Demand
Reuters • 8 months ago
Premium access

Complete news archive for Panacea Biotec

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Panacea Biotec on our blog

Frequently Asked Questions about Panacea Biotec

Panacea Biotec was founded in 1984 and raised its 1st funding round 27 years after it was founded.

Panacea Biotec is headquartered in Ambala, India. It is registered at Ambala, Haryana, India.

Panacea Biotec has 1,290 employees.

The primary company behind Panacea Biotec, Panacea Biotec Limited, reported revenue of ₹676 Cr for FY 2026, up 14% year on year.

Panacea Biotec involved in research, manufacturing and marketing of branded pharmaceutical formulations, vaccines, biosimilars (antibodies, proteins) and natural products. The product portfolio includes prescription products in therapeutic areas like pain management, diabetes, cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastrointestinal care products and vaccines.

Panacea Biotec's top competitors include Syngene and Piramal Group.

Yes, Panacea Biotec is publicly traded on NSE under the ticker symbol PANACEABIO.

Panacea Biotec has 1 investor. Key investors include India Resurgence Fund.

Panacea Biotec is associated with 2 legal entities: Panacea Biotec Limited, Panacea Biotec Pharma Limited.

The legal entities of Panacea Biotec currently have 13 directors, including Ankesh Jain, Rajesh Jain, Manjula Upadhyay and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available